If you’re looking for a simple and straightforward scone recipe that delivers perfect results every time, this might be the one. Mary Berry’s classic scone recipe makes 10 delicious scones ...

While scone recipes can be tricky to perfect, Danielle Ellis, a French-trained baker and the voice behind Severn Bites, claims that with the right ingredients, they will turn out "perfect".

Trainer Cassandra Stummer is confident two-year old filly Lighthouse Lass can put her best foot forward when she makes her racing debut in the Select Events 2YO Handicap (900m) at Scone on Thursday.

Sometimes I forget how British I am until I say things like, "Oh, I could just go for a scone with jam and cream". And after writing about Paul Hollywood's three golden rules for making the ...

Scones are a classic food to bake and easy for novice bakers to have a go at. But if you want to get them right first time or perhaps perfect the recipe you have been using, a Great British Bake ...

Tonight will be cloudy with a few spots of light rain pushing eastwards at times, before turning drier towards dawn. It will be a mild and breezy night. Sunday Tomorrow will have a cloudy start ...

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

(Reuters) - Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Jan 10 (Reuters) - Drugmaker Biogen (BIIB.O), opens new tab will buy all outstanding shares of Sage Therapeutics (SAGE.O), opens new tab that it does not already own for $7.22 apiece, a filing ...

Vanessa Leroy / Bloomberg via Getty Images Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.